573 - CD388, a Novel Drug-Fc Conjugate (DFC), Demonstrates Prophylactic Activity in an Influenza Human Challenge Model

Saturday, October 19, 2024

2:21 PM – 2:39 PM US PT

Location: 408 A

Co-Author(s)

OE

Ozlem Equils, MD

Senior Medical Director
Cidara Therapeutics
San Diego, California, United States

Co-Author(s)

Shawn Flanagan, PhD (he/him/his)

VP, Clinical Pharmacology and Early Development
Cidara Therapeutics
San Diego, CA, United States
SW

Sy-Shi Wang, Ph.D.

Janssen Pharmaceutical
Brisbane, California, United States
JV

Johan Vingerhoets, PhD

Janssen Pharmaceutica NV, Infectious Diseases and Vaccines
Beerse, Brussels Hoofdstedelijk Gewest, Belgium
Wv

Wilbert van Duijnhoven, n/a

Janssen Pharmaceutica NV
Beerse, Brussels Hoofdstedelijk Gewest, Belgium
AM

Alex James Mann, MSc

hVIVO
London, England, United Kingdom
RR

Roxana E. Rojas, M.D., Ph.D.

Senior Medical Director
Janssen Research & Development
Brisbane, California, United States

Presenting Author(s)

Taylor Sandison, MD, MPH (he/him/his)

Chief Medical Officer
Cidara Therapeutics
San Diego, CA, United States

Slides

Disclosure(s):

Ozlem Equils, MD: Cidara Therapeutics: Employee, Stocks/Bonds (Public Company)

Shawn Flanagan, PhD: Cidara Therapeutics: Employee, Salaried Employee, Stocks/Bonds (Public Company), Stocks/Bonds (Public Company)

Sy-Shi Wang, Ph.D.: Janssen Research & Development LLC: Employee, Stocks/Bonds (Public Company)

Johan Vingerhoets, PhD: Janssen Pharmaceutica NV: Stocks/Bonds (Public Company)

Wilbert van Duijnhoven, n/a: Janssen Pharmaceutica NV: Employee, Stocks/Bonds (Public Company)

Alex James Mann, MSc: hVIVO: Employee

Roxana E. Rojas, M.D., Ph.D.: Janssen Research & Development LLC: Employee, Stocks/Bonds (Public Company); Johnson and Johnson: Stocks/Bonds (Public Company)

Taylor Sandison, MD, MPH: Cidara Therapeutics Inc: Employee, Stocks/Bonds (Public Company)